Sphingomyelin Phosphodiesterase
"Sphingomyelin Phosphodiesterase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the hydrolysis of sphingomyelin to ceramide (N-acylsphingosine) plus choline phosphate. A defect in this enzyme leads to NIEMANN-PICK DISEASE. EC 3.1.4.12.
| Descriptor ID |
D013108
|
| MeSH Number(s) |
D08.811.277.352.640.750
|
| Concept/Terms |
Sphingomyelin Phosphodiesterase- Sphingomyelin Phosphodiesterase
- Sphingomyelin Cleaving Enzyme
- Sphingomyelinase C
- Sphingomyelinase
- Sphingomyelin Cholinephosphohydrolase
|
Below are MeSH descriptors whose meaning is more general than "Sphingomyelin Phosphodiesterase".
Below are MeSH descriptors whose meaning is more specific than "Sphingomyelin Phosphodiesterase".
This graph shows the total number of publications written about "Sphingomyelin Phosphodiesterase" by people in this website by year, and whether "Sphingomyelin Phosphodiesterase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sphingomyelin Phosphodiesterase" by people in Profiles.
-
Smpd3 Expression in both Chondrocytes and Osteoblasts Is Required for Normal Endochondral Bone Development. Mol Cell Biol. 2016 09 01; 36(17):2282-99.
-
Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J Am Soc Nephrol. 2015 Jan; 26(1):133-47.
-
Platelet activating factor-induced ceramide micro-domains drive endothelial NOS activation and contribute to barrier dysfunction. PLoS One. 2013; 8(9):e75846.
-
Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int. 2013 Nov; 84(5):1025-33.
-
Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011 Jun 01; 3(85):85ra46.
-
Fibrillar amyloid-beta-activated human astroglia kill primary human neurons via neutral sphingomyelinase: implications for Alzheimer's disease. J Neurosci. 2010 Sep 22; 30(38):12676-89.
-
Oxidative stress kills human primary oligodendrocytes via neutral sphingomyelinase: implications for multiple sclerosis. J Neuroimmune Pharmacol. 2007 Jun; 2(2):184-93.
-
Human immunodeficiency virus type 1 gp120 induces apoptosis in human primary neurons through redox-regulated activation of neutral sphingomyelinase. J Neurosci. 2004 Oct 27; 24(43):9531-40.
-
Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Implications for Alzheimer's disease. J Biol Chem. 2004 Dec 03; 279(49):51451-9.
-
Induction of the manganese superoxide dismutase gene by sphingomyelinase and ceramide. J Neurochem. 1999 Aug; 73(2):513-20.